An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate
Hormone refractory prostate cancer refers to advanced disease in which the patient no longer
responds to conventional hormonal treatment. When hormone therapy is no longer successful,
chemotherapy is a treatment option. However, current single-agent treatment has shown to
have limited benefit. In this clinical trail, investigators are evaluating the effectiveness
of Zoledronate(Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment
of patients with hormone refractory prostate cancer. Zometa is a bisphosphonate, and may
reduce or delay skeletal complications caused by bone metastases. Estramustine and Taxotere
are chemotherapy drugs that have shown activity in hormone refractory prostate cancer.
Eligible patients will be randomized to receive Estramustine and Docetaxel (Taxotere) in
combination with Zometa or Zometa given alone.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess and compare the effect of zoledronate and docetaxel/estramustine on markers of bone metabolism in patients with hormone-refractory prostate cancer.
David C. Smith, MD
University of Michigan Cancer Center
United States: Institutional Review Board
|The University of Michigan Comprehensive Cancer Center||Ann Arbor, Michigan 48109|